Cognitive impairment without dementia: A current view of the problem
https://doi.org/10.14412/2074-2711-2017-2-71-76
Abstract
In recent decades, special attention is given to cognitive impairments (CIs) without dementia, which include moderate (MCI), mild, and subjective ones. Epidemiological studies suggest that the prevalence of CI is high in elderly people (10–15%) and patients at an outpatient reception (as high as 70%). CIs are more frequently caused by Alzheimer's disease, cerebrovascular disease, and their concurrence. In patients with MCI, dementia occurs in 10–15% of cases during a year. Correction of vascular risk factors allows the progression of CI to be curbed. The paper discusses the use of EGB761® in patients with CI.
About the Author
Yu. A. Starchina
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow
Russian Federation
Russian Federation
Department of Nervous System Diseases and Neurosurgery
11, Rossolimo St., Moscow 119021
References
1. Schaller S, Mauskopf J, Kriza C, et al. The main cost drivers in dementia: A systematic review. Int J Geriatr Psychiatry. 2015 Feb;30(2):111-29. doi: 10.1002/gps.4198. Epub 2014 Oct 16.
2. Wimo A, JЪnsson L, Bond J, et al. The worldwide economic impact of dementia 2010. Alzheimers Dement. 2013 Jan;9(1):1-11.e3. doi: 10.1016/j.jalz.2012.11.006.
3. Busse A, Hensel A, Gü hne U, et al. Mild cognitive impairment: long-term course of four clinical subtypes. Neurology. 2006 Dec 26;67(12):2176-85.
4. Di Carlo A, Lamassa M, Baldereschi M, et al. CIND and MCI in the Italian elderly: frequency, vascular risk factors, progression to dementia. Neurology. 2007 May 29;68(22): 1909-16.
5. Ganguli M, Chang CC, Snitz BE, et al. Prevalence of mild cognitive impairment by multiple classifications: The Monongahela-Youghiogheny Healthy Aging Team (MYHAT) project. Am J Geriatr Psychiatry. 2010 Aug;18(8): 674-83. doi: 10.1097/JGP.0b013e3181cdee4f.
6. Larrieu S, Letenneur L, Orgogozo JM, et al. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology. 2002 Nov 26;59(10):1594-9.
7. Roberts RO, Geda YE, Knopman DS, et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology. 2008;30(1):58-69. doi: 10.1159/000115751. Epub 2008 Feb 7.
8. Захаров ВВ. Дофаминергическая и норадре- нергическая терапия когнитивных нарушений. Журнал неврологии и психиатрии им. С.С. Корсакова. 2006;(9):43-7. [Zakharov VV. Dopaminergic and noradrenergic therapy of cognitive impairment. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2006;(9):43-7. (In Russ.)].
9. Petersen RS, Smith GE, Waring SC, et al. Aging, memory and mild cognitive impairment. Int Psychogeriatr. 1997;9 Suppl 1:65-9.
10. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004 Sep;256(3): 183-94.
11. Petersen RS, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999 Mar;56(3):303-8.
12. Petersen RC, Knopman DS, Boeve BF, et al. Mild cognitive impairment: 10 years later. Arch Neurol. 2009 Dec;66(12):1447-55. doi: 10.1001/archneurol.2009.266.
13. Захаров ВВ, Парфенов ВА, Преображенская ИС. Когнитивные расстройства. Москва: Ремедиум; 2015. 192 с. [Zakharov VV, Parfenov VA, Preobrazhenskaya IS. Kognitivnye rasstroistva [Cognitive disorders]. Moscow: Remedium; 2015. 192 p.]
14. Захаров ВВ. Эволюция когнитивного дефицита: легкие и умеренные когнитивные нарушения. Неврология, нейропсихиатрия, психосоматика. 2012;4(2):16-21. [Zakharov VV. Evolution of cognitive deficit: mild and moderate cognitive impairments. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2012;4(2):16-21. (In Russ.)]. doi: 10.14412/2074-2711-2012-376
15. Яхно НН. Когнитивные расстройства в неврологической клинике. Неврологический журнал. 2006;11(Прил 1):4-12. [Yakhno NN. Cognitive impairments in neurological clinic. Nevrologicheskii zhurnal. 2006;11(Pril 1):4-12. (In Russ.)].
16. Reisberg B, Shulman MB, Torossian C, et al. Outcome over seven years of healthy adults with and without subjective cognitive impairment. Alzheimers Dement. 2010 Jan;6(1):11-24. doi: 10.1016/j.jalz.2009.10.002.
17. Jessen F, Wiese B, Bickel H, et al for the AgeCoDe Study Group. Prediction of dementia in primary care patients. PLoS One. 2011 Feb 18; 6(2):e16852. doi: 10.1371/journal.pone.0016852.
18. Dufouil C, Fuhrer R, Alpеrovitch A. Subjective cognitive complaints and cognitive decline: Consequence or predictor? The epidemiology of vascular aging study. J Am Geriatr Soc. 2005 Apr;53(4):616-21.
19. Mitchell AJ, Beaumont H, Ferguson D, et al. Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: Meta-analysis. Acta Psychiatr Scand. 2014 Dec;130(6):439-51. doi: 10.1111/acps.12336. Epub 2014 Sep 13.
20. Jessen F, Feyen L, Freymann K, et al. Volume reduction of the entorhinal cortex in subjective memory impairment. Neurobiol Aging. 2006 Dec;27(12):1751-6. Epub 2005 Nov 23.
21. Saykin AJ, Wishart HA, Rabin LA, et al. Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI. Neurology. 2006 Sep 12;67(5):834-42.
22. Striepens N, Scheef L, Wind A, et al. Volume loss of the medial temporal lobe structures in subjective memory impairment. Dement Geriatr Cogn Disord. 2010;29(1):75-81. doi: 10.1159/000264630. Epub 2010 Jan 28.
23. Mosconi L, De Santi S, Brys M, et al. Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biol Psychiatry. 2008 Mar 15;63(6):609-18. Epub 2007 Aug 27.
24. Perrotin A, Mormino EC, Madison CM, et al. Subjective cognition and amyloid deposition imaging: A Pittsburgh Compound B positron emission tomography study in normal elderly individuals. Arch Neurol. 2012 Feb;69(2):223-9. doi: 10.1001/archneurol.2011.666.
25. Amariglio RE, Becker JA, Carmasin J, et al. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia. 2012 Oct;50(12):2880-6. doi: 10.1016/j.neuropsychologia.2012.08.011. Epub 2012 Aug 23.
26. van Harten AC, Visser PJ, Pijnenburg YA, et al. Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints. Alzheimers Dement. 2013 Sep;9(5):481-7. doi: 10.1016/j.jalz.2012.08.004. Epub 2012 Dec 8.
27. Jessen F, Amariglio RE, van Boxtel M, et al; Subjective Cognitive Decline Initiative (SCD-I) Working Group. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement. 2014 Nov;10(6):844-52. doi: 10.1016/j.jalz.2014.01.001. Epub 2014 May 3.
28. Яхно НН, Локшина АБ, Захаров ВВ. Легкие и умеренные когнитивные расстройства при дисциркуляторной энцефалопатии. Клиническая геронтология. 2005;11(9):38—9. [Yakhno NN, Lokshina AB, Zakharov VV. Light and moderate cognitive disorders in dyscirculatory encephalopathy. Klinicheskaya gerontologiya. 2005;11(9):38—9. (In Russ.)].
29. Saczynski JS, Beiser A, Seshadri S, et al. Depressive symptoms and risk of dementia: the Framingham Heart Study. Neurology. 2010 Jul 6;75(1):35-41. doi: 10.1212/WNL.0b013e 3181e62138.
30. Dotson VM, Beydoun MA, Zonderman AB. Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment. Neurology. 2010 Jul 6;75(1):27-34. doi: 10.1212/WNL.0b013e3181e62124.
31. Alzheimer’s Association. 2017 Alzheimer’s Disease Facts and Figures. Alzheimers Dement. 2017;13:325-73.
32. Парфенов ВА, Старчина ЮА, Яхно НН. Эпросартан (теветен) в профилактике повторного инсульта и когнитивных нарушений. Неврологический журнал. 2007;(1):46–51. [Parfenov VA, Starchina YuA, Yakhno NN. Eprosartan (Teveten) in the prevention of recurrent stroke and cognitive impairment. Nevrologicheskii zhurnal. 2007;(1): 46–51. (In Russ.)].
33. Парфенов ВА, Хасанова ДР. Ишемический инсульт. Москва: МИА; 2012. 288 с. [Parfenov VA, Khasanova DR. Ishemicheskii insul't [Ischemic stroke]. Moscow: MIA; 2012. 288 p.]
34. Gao Y, O'Caoimh R, Healy L, et al. Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia. BMJ Open. 2013 Jul 25;3(7). pii: e002881. doi: 10.1136/bmjopen-2013- 002881. Print 2013.
35. James PA, Oparil S, Carter BL, et al. 014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 Feb 5; 311(5):507-20. doi: 10.1001/jama.2013.284427.
36. Amieva H, Ouvrard C, Giulioli C, et al. Self-Reported Hearing Loss, Hearing Aids, and Cognitive Decline in Elderly Adults: A 25-Year Study. J Am Geriatr Soc. 2015 Oct;63(10): 2099-104. doi: 10.1111/jgs.13649.
37. Uchida Y, Nishita Y, Tange C, Sugiura S. The Longitudinal Impact of Hearing Impairment on Cognition Differs According to Cognitive Domain. Front Aging Neurosci. 2016 Aug 22;8:201. doi: 10.3389/fnagi.2016.00201. eCollection 2016.
38. Fritze T, Teipel S, Ovari A, et al. Hearing Impairment Affects Dementia Incidence. An Analysis Based on Longitudinal Health Claims Data in Germany. PLoS One. 2016 Jul 8;11(7): e0156876. doi: 10.1371/journal.pone.0156876. eCollection 2016.
39. Jefferis JM, Mosimann UP, Clarke MP. Cataract and Cognitive Impairment: A Review of the Literature. Br J Ophthalmol. 2011 Jan;95(1): 17-23. doi: 10.1136/bjo.2009.165902. Epub 2010 Aug 31.
40. Roberts RO, Cha RH, Mielke MM, et al. Risk and protective factors for cognitive impairment in persons aged 85 years and older. Neurology. 2015 May 5;84(18):1854-61. doi: 10.1212/WNL. 0000000000001537. Epub 2015 Apr 8.
41. Andel R, Crowe M, Pedersen NL, et al. Physical exercise at midlife and risk of dementia three decades later: a population-based study of Swedish twins. J Gerontol A Biol Sci Med Sci. 2008 Jan; 63(1):62-6.
42. Ahlskog JE, Geda YE, Graff-Radford NR, et al. Physical Exercise as a Preventive or DiseaseModifying Treatment of Dementia and Brain Aging. Mayo Clin Proc. 2011 Sep;86(9):876-84. doi: 10.4065/mcp.2011.0252.
43. Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomized controlled trial. Lancet. 2015 Jun 6;385(9984): 2255-63. doi: 10.1016/S0140-6736(15)60461-5. Epub 2015 Mar 12.
44. Дамулин ИВ. Болезнь Альцгеймера и сосудистая деменция. Под ред. Н.Н. Яхно. М., 2002. 85 с.
45. Russ TC, Morling JM. Cholinesterase inhibitors for mild cognitive impairment. Cochrane Database Syst Rev. 2012 Sep 12;(9):CD009132. doi: 10.1002/14651858.CD009132.pub2.
46. Diniz BS, Pinto JA, Gonzaga MC. To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci. 2009 Jun;259(4):248-56. doi: 10.1007/ s00406-008-0864-1. Epub 2009 Feb 17.
47. Russ TC. Cholinesterase Inhibitors Should Not Be Prescribed for Mild Cognitive Impairment. Evid Based Med. 2014 Jun;19(3):101. doi: 10.1136/ eb-2013-101687. Epub 2014 Jan 30.
48. Oken BS, Storzbach DM, Kaye JA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol. 1998 Nov; 55(11):1409-15.
49. DeFeudis FV, and Drieu K. Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Curr Drug Targets. 2000 Jul;1(1):25-58.
50. Tchantchou F, Lacor PN, Cao Z, et al. Stimulation of neurogenesis and synaptogenesis by bilobalide and quercetin via common final pathway in hippocampal neurons. J Alzheimers Dis. 2009; 18(4):787-98. doi: 10.3233/JAD-2009-1189.
51. Tchantchou F, Xu Y, Wu Y, Christen Y et al. EGb 761 enhances adult hippocampal neurogenesis and phosphorylation of CREB in transgenic mouse model of Alzheimer's disease. FASEB J. 2007 Aug;21(10):2400-8. Epub 2007 Mar 13.
52. Altamura C, Scrascia F, Quattrocchi CC, et al. Regional MRI diffusion, white-matter hyperintensities, and cognitive function in Alzheimer's disease and vascular dementia. J Clin Neurol. 2016 Apr;12(2):201-8. doi: 10.3988/jcn.2016.12.2.201.
53. Zhang HF, Huang LB, Zhong YB, et al. An Overview of Systematic Reviews of Ginkgo biloba Extracts for Mild Cognitive Impairment and Dementia. Front Aging Neurosci. 2016 Dec 6;8:276. doi: 10.3389/fnagi.2016.00276. eCollection 2016.
54. Grass-Kapanke B, Busmane A, Lasmanis A, et al. Effects of Ginkgo biloba special extract EGb 761 in Very Mild Cognitive Impairment (vMCI). Neurosci. Med. 2011;(2):48-56.
55. Vellas B, Coley N, Ousset PJ, et al. Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol. 2012 Oct;11(10):851-9. doi: 10.1016/S1474- 4422(12)70206-5. Epub 2012 Sep 6.
56. Amieva H, Meillon C, Helmer C, et al. Gingko biloba extract and long term cognitive decline: a 20 years follow up population based study. PLoS One. 2013;8(1):e52755. doi: 10.1371/journal.pone.0052755. Epub 2013 Jan 11.
57. Парфенов ВА, Старчина ЮА. Лечение танаканом неврологических расстройств у больных с артериальной гипертензией. Русский медицинский журнал. 2005;(22):1462-5. [Parfenov VA, Starchina YuA. Tanakan in the treatment of neurological disorders in patients with arterial hypertension. Russkii meditsinskii zhurnal. 2005;(22):1462-5. (In Russ.)].
58. Старчина ЮА, Парфенов ВА, Чазова ИЕ и др. Когнитивные функции и эмоциональное состояние больных, перенесших инсульт, на фоне антигипертензивной терапии. Журнал неврологии и психиатрии им. С.С. Корсакова. 2005;(15):39-44. [Starchina YuA, Parfenov VA, Chazova IE, et al. Cognitive function and emotional status of stroke patients on the background of antihypertensive therapy. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2005;(15):39-44. (In Russ.)].
Review
For citations:
Starchina Yu.A. Cognitive impairment without dementia: A current view of the problem. Neurology, Neuropsychiatry, Psychosomatics. 2017;9(2):71-76. (In Russ.) https://doi.org/10.14412/2074-2711-2017-2-71-76
Views: 755
Email this article 